News

The efficacy of ruxolitinib cream in pediatric patients shows that nonsteroidal management of atopic dermatitis is feasible, ...
New data highlight efficacy, safety, and time off treatment with as-needed ruxolitinib cream in pediatric atopic dermatitis.
FDA approves Arcutis’ Zoryve ® (roflumilast) cream 0.15% for the treatment of atopic dermatitis in adults and children down to 6 years of age. News release. July 9, 2024.
One in 10 people with atopic dermatitis, the most common type of eczema, have symptoms on their feet. These quick facts can help you manage it.
FDA accepts Arcutis’ supplemental New Drug Application for roflumilast cream 0.15% for the treatment of atopic dermatitis in adults and children down to age 6. News release. Arcutis ...
Vtama cream 1% has been approved in Japan for the treatment of adults with psoriasis as well as patients aged 12 years and older with atopic dermatitis, Dermavant Sciences announced in a press ...